- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.BioPharma Dive · 1mo ago↗ source
- Summit withdraws $500M offering, citing 'market conditions'The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 million…Endpoints · 1mo ago↗ source
- Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyPlus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.”…